EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effects of the CYP3A inhibitors, voriconazole, itraconazole, and fluconazole on the pharmacokinetics of osimertinib in rats

Yutao Lou, Feifeng Song, Mengting Cheng, Ying Hu, Yitao Chai, Qing Hu, Qiyue Wang, Hongying Zhou, Meihua Bao, Jinping Gu, Yiwen Zhang

PeerJ · 2023

DOI: 10.7717/peerj.15844 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PeerJ, 2023. Verfasst von Yutao Lou und 10 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Zhejiang University of Technology, Hanghzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Itraconazole, Lung Neoplasms. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Zhejiang Provincial Natural Science Foundation of China, Chinese Medicine Research Program of Zhejiang Province, Medical and Health Research Program of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Osimertinib, as third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is the first-line treatment approved to treat advanced T790M mutation-positive tumors. Triazole antifungals are therapeutic drugs for cancer patients to reduce the risk of opportunistic fungal infections. Our objective was to investigate whether three triazole antifungals (voriconazole, itraconazole, and fluconazole) could change the pharmacokinetics of osimertinib in rats.

Methods

The adult male Sprague-Dawley rats were randomly divided into four groups ( n = 6): control (0.3% CMC-Na), and voriconazole (20 mg/kg), itraconazole (20 mg/kg), or fluconazole (20 mg/kg) combined with osimertinib (10 mg/kg) group. Tail vein blood samples were collected into heparin tubes at various time points within 0–48 h after osimertinib administration. Osimrtinib’s plasma concentration was detected using HPLC-MS/MS system equipped with a Waters XBridge C 18 column, with the mobile phase consisting of acetonitrile and 0.2% formic acid water at a flow rate of 0.5 mL/min.

Results

Co-administration with voriconazole or fluconazole increased the C max of osimertinib by 58.04% and 53.45%, respectively; the AUC 0–t increased by 62.56% and 100.98%, respectively. However, when co-administered with itraconazole, the C max and AUC 0–t of osimertinib only increased by 13.91% and 34.80%, respectively.

Conclusions

Our results revealed that the pharmacokinetics of osimertinib were significantly changed by voriconazole and fluconazole in rats, whereas it was slightly affected by itraconazole. This work will contribute to a more comprehensive understanding of the pharmacokinetic properties of osimertinib when co-administered with triazole antifungals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ItraconazoleLung NeoplasmsMaleRatsAnimalsVoriconazoleFluconazoleAntifungal AgentsCytochrome P-450 CYP3A InhibitorsTandem Mass SpectrometryErbB ReceptorsRats, Sprague-DawleyProtein Kinase InhibitorsMutationTriazolesAcrylamidesAniline CompoundsIndolesPyrimidines

Stichwörter der Autor:innen

FluconazoleHPLC-MS/MSItraconazoleOsimertinibPharmacokineticsVoriconazole

Substanzen

ItraconazoleVoriconazoleFluconazoleAntifungal AgentsCytochrome P-450 CYP3A InhibitorsErbB ReceptorsProtein Kinase InhibitorsTriazolesosimertinibAcrylamides

Autor:innen und Institutionen

  • College of Pharmacy, Zhejiang University of Technology, Hanghzhou, Zhejiang, China.
  • Clinical Pharmacy Center, Department of Pharmacy, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.
  • Department of Oncology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.
  • Hunan Key Laboratory of the Research and Development of Novel Pharmaceutical Preparations, Changsha Medical University, Changsha, Hunan, China.
  • Key Laboratory of Endocrine Gland Diseases of Zhejiang Province, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.

Förderung

  • Zhejiang Provincial Natural Science Foundation of China
  • Chinese Medicine Research Program of Zhejiang Province
  • Medical and Health Research Program of Zhejiang Province

Zitieren

APA

Lou, Y., Song, F., Cheng, M., Hu, Y., Chai, Y., Hu, Q., Wang, Q., Zhou, H., Bao, M., Gu, J., & Zhang, Y. (2023). Effects of the CYP3A inhibitors, voriconazole, itraconazole, and fluconazole on the pharmacokinetics of osimertinib in rats. PeerJ. https://doi.org/10.7717/peerj.15844

Vancouver

Lou Y, Song F, Cheng M, Hu Y, Chai Y, Hu Q, et al. Effects of the CYP3A inhibitors, voriconazole, itraconazole, and fluconazole on the pharmacokinetics of osimertinib in rats. PeerJ. 2023. doi:10.7717/peerj.15844

BibTeX
@article{Lou2023,
  author = {Lou, Yutao and Song, Feifeng and Cheng, Mengting and Hu, Ying and Chai, Yitao and Hu, Qing and Wang, Qiyue and Zhou, Hongying and Bao, Meihua and Gu, Jinping and Zhang, Yiwen},
  title = {Effects of the CYP3A inhibitors, voriconazole, itraconazole, and fluconazole on the pharmacokinetics of osimertinib in rats},
  journal = {PeerJ},
  year = {2023},
  doi = {10.7717/peerj.15844}
}
Kostenlos starten →